Victory Capital Management’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-12,825
| Closed | -$2.83M | – | 2424 |
|
|
2025
Q4 | $2.83M | Sell |
12,825
-23,804
| -65% | -$3.85M | ﹤0.01% | 1495 |
|
|
2025
Q3 | $3.51M | Buy |
+36,629
| New | +$2.34M | ﹤0.01% | 1439 |
|
|
2020
Q2 | – | Sell |
-272
| Closed | -$13K | – | 2637 |
|
|
2020
Q1 | $13K | Buy |
+272
| New | +$16.3K | ﹤0.01% | 2989 |
|
|
2019
Q4 | – | Sell |
-174
| Closed | -$7K | – | 2740 |
|
|
2019
Q3 | $7K | Buy |
+174
| New | +$5.85K | ﹤0.01% | 3364 |
|
|
2019
Q2 | – | Sell |
-127
| Closed | -$7K | – | 1830 |
|
|
2019
Q1 | $7K | Hold |
127
| – | – | ﹤0.01% | 1768 |
|
|
2018
Q4 | $6K | Hold |
127
| – | – | ﹤0.01% | 1774 |
|
|
2018
Q3 | $11K | Buy |
127
+17
| +15% | +$1.5K | ﹤0.01% | 1780 |
|
|
2018
Q2 | $11K | Hold |
110
| – | – | ﹤0.01% | 1808 |
|
|
2018
Q1 | $9K | Hold |
110
| – | – | ﹤0.01% | 1809 |
|
|
2017
Q4 | $15K | Hold |
110
| – | – | ﹤0.01% | 1795 |
|
|
2017
Q3 | $18K | Hold |
110
| – | – | ﹤0.01% | 1780 |
|
|
2017
Q2 | $17K | Buy |
110
+2
| +2% | +$276 | ﹤0.01% | 1776 |
|
|
2017
Q1 | $17K | Buy |
108
+26
| +32% | +$4.57K | ﹤0.01% | 1779 |
|
|
2016
Q4 | $17K | Buy |
+82
| New | +$17K | ﹤0.01% | 1766 |
|
Victory Capital Management's CDTX Position: Q1 2026 in Review
Victory Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 12,825 shares — an estimated $2.83M sold.
Victory Capital Management first reported a position in CDTX in Q4 2016 and held it in 14 quarters. The position peaked at $3.51M in Q3 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Victory Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Victory Capital Management sold 12,825 Cidara Therapeutics shares in Q1 2026, an estimated $2.83M.
- Victory Capital Management first reported a position in Cidara Therapeutics in Q4 2016 and held it in 14 quarters.
- Victory Capital Management's Cidara Therapeutics position peaked at $3.51M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.